CN Patent

CN114306234A — 一种含有加巴喷丁复合物的tpgs胶束口服液及其制备方法

Assigned to Jiangsu Baiaoxinkang Pharmaceutical Technology Co ltd · Expires 2022-04-12 · 4y expired

What this patent protects

本发明涉及一种含有加巴喷丁复合物的TPGS胶束口服液，其中加巴喷丁复合物是由加巴喷丁和脂肪酸或者由加巴喷丁、脂肪酸盐和盐酸来制备。所制备的含有加巴喷丁复合物的TPGS胶束口服液可有效地降低加巴喷丁分子内缩合物内酰胺的生成，提高了药物稳定性，且掩盖了加巴喷丁的苦味，提高了患者的顺应性。

USPTO Abstract

本发明涉及一种含有加巴喷丁复合物的TPGS胶束口服液，其中加巴喷丁复合物是由加巴喷丁和脂肪酸或者由加巴喷丁、脂肪酸盐和盐酸来制备。所制备的含有加巴喷丁复合物的TPGS胶束口服液可有效地降低加巴喷丁分子内缩合物内酰胺的生成，提高了药物稳定性，且掩盖了加巴喷丁的苦味，提高了患者的顺应性。

Drugs covered by this patent

Patent Metadata

Patent number
CN114306234A
Jurisdiction
CN
Classification
—
Expires
2022-04-12
Drug substance claim
No
Drug product claim
No
Assignee
Jiangsu Baiaoxinkang Pharmaceutical Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.